(Q36945011)

17 August 2017

1 reference

title

Safety of aerosolized amphotericin B. (English)

1 reference

17 August 2017

Stephanie A Knechtel

1

1 reference

17 August 2017

Michael E Klepser

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Drug Safety

17 August 2017

published in

1 reference

17 August 2017

volume

6

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

523-532

1 reference

The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Aspergillus infections in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Pharmacokinetics of aerosol amphotericin B in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Amphotericin B disposition after aerosol inhalation in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Safety of aerosolized amphotericin B lipid complex in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.523

21 January 2018

Identifiers

DOI

10.1517/14740338.6.5.523

1 reference

17 August 2017

1 reference